Fenofibrate in primary biliary cirrhosis: A pilot study

Open Cardiovascular Medicine Journal

Volumn 4, Issue , 2010, Pages 120-126

  Liberopoulos, E N ^a   Florentin, M ^a,b   Elisaf, M S ^a   Mikhailidis, D P ^b   Tsianos, E ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Dyslipidemia; Fibrates; Liver enzymes; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATININE; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78249246788     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010120     Document Type: Article

References (49)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
2. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-836.
3. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053-1060.
4. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38: 573-578.
5. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 2002; 97: 212-214.
6. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95: 2990-2992.
7. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95: 326-327.
8. Ohmoto K, Mitsui Y, Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 2001; 21: 223-224.
9. Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafi- brate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol 2006; 41: 502-503.
10. Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002; 97: 1075-1077.
11. Miyaguchi S, Ebinuma H, Imaeda H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000; 47: 1518-1521.
12. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51: 265-269.
13. Kusuoka H, Hoffman JI. Advice on statistical analysis for circulation research. Circ Res 2002; 91: 662-671.
14. Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006; 41: 686-692.
15. Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxy-cholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 2008; 38: 557-564.
16. Nakamuta M, Enjoji M, Kotoh K, Shimohashi N, Tanabe Y. Longterm fibrate treatment for PBC. J Gastroenterol 2005; 40: 546-547.
17. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
18. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin 2000; 16: 21-32.
19. Feussner G, Kurth B, Lohrmann J. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyper- lipoproteinemia. Eur J Med Res 1997; 2: 165-168.
20. Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97: 2147-2149.
21. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10: 894-898.
22. Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long- term prognosis in primary biliary cirrhosis. Hepatology 2009; 49: 337-338.
23. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
24. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPAR-gamma activators. Nature 1998; 393: 790-793.
25. Calabresi L, Franceschini G, Sirtori CR, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238: 61-65.
26. Gulubova M, Vlaykova T, Manolova I, Hadjipetkov P, Popharitov A. Implication of adhesion molecules in inflammation of the common bile duct in patients with secondary cholangitis due to biliary obstruction. Hepatogastroenterology 2008; 55: 836-841.
27. Chianale J, Vollrath V, Wielandt AM, et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996; 314 (Pt 3): 781-786.
28. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-462.
29. Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I. Bile acids regulate RANTES gene expression through its cognate NF-kappaB binding sites. Biochem Biophys Res Commun 2001; 288: 1095-101.
30. Hirano F, Kobayashi A, Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int Immunopharmacol 2003; 3: 225-232.
31. Hirano Y, Hirano F, Fujii H, Makino I. Fibrates suppress chenode-oxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation. Eur J Pharmacol 2002; 448: 19-26.
32. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des 2008; 14: 574-587.
33. Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008; 103: 2784-2788.
34. Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly 2008; 138: 415-419.
35. Longo M, Crosignani A, Podda M. Hyperlipidemia in Chronic Cholestatic Liver Disease. Curr Treat Options Gastroenterol 2001; 4: 111-114.
36. Del Puppo M, Galli Kienle M, Crosignani A, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001; 42: 437-441.
37. Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36: 454-458.
38. Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2009 Sep 6 [Epub ahead of print].
39. Rajab MA, Kaplan MM. Statins in Primary Biliary Cirrhosis: Are They Safe? Dig Dis Sci 2009 Oct 1 [Epub ahead of print].
40. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholes-terolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46: 1453-1463.
41. Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46: 776-784.
42. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
43. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883.
44. Strasak AM, Kelleher CC, Klenk J, et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 2008; 28: 1857-1865.
45. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112: 2130-2137.
46. Lee DH, Silventoinen K, Hu G, et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006; 27: 2170-2176.
47. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men with-out diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008; 201: 168-175.
48. Korantzopoulos P, Tzimas P, Kalantzi K, et al. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582-589.
49. Lippi G, Targher G, Montagnana M, Salvagno GL, Guidi GC. Relationship between gamma-glutamyltransferase, lipids and lipoprotein(a) in the general population. Clin Chim Acta 2007; 384: 163-166.